Joshua M. Tarnoff

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman on March 28, 2002 and is headquartered in Salt Lake City, UT.

Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE.

Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Connecticut Academy of Science & Engineering engages in the provision of advising state government and industry in the application of science and engineering. It offers studies on public policy issues, general assembly, and private organizations. The company was founded in 1976 and is headquartered in Hartford, CT.

New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA.

The United Nations High Commissioner for Refugees, also known as UNHCR, is an organization that is committed to protecting the rights of refugees, forcibly displaced communities, and stateless individuals. The non-profit company is based in Suisse, Switzerland. The Swiss company's mission is to save lives and provide assistance to those who have been forced to flee their homes due to conflict, persecution, or other forms of violence.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann.

Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA.

Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD.

GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom.

TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France.

New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.

Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC.

Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA.

Avoro Ventures LLC (Avoro Ventures) is a venture capital subsidiary of Avoro Capital Advisor LLC founded in 2020. The firm is headquartered in New York.

Enavate Sciences is a platform created by Patient Square Capital that supports therapeutic companies advancing medicines and enabling technologies to address patient needs. Enavate Sciences is based in New York, NY. The company provides capital support and operational experience to a diverse portfolio of therapeutics companies, aiming to accelerate innovation. James P. Boylan has been the CEO of the company since 2022.